Teva Respiratory says that the ProAir HFA metered dose inhaler with dose counter for the treatment of asthma is now available. The albuterol MDI with dose counter was approved by the FDA in March 2012. At the time, the company announced that the new inhaler would be available by the end of 2012. Teva says that it needed time to manufacture a sufficient inventory to allow for a complete conversion to the new product.
The original ProAir HFA inhaler without dose counter was approved in 2004. The FDA issued a guidance on “Integration of Dose-Counting Mechanisms into MDI Drug Products” in March 2003.
Teva Global Respiratory Research and Development Senior VP Tushar Shah commented, “As the market leader in quick-relief inhalers, we are pleased to offer patients the latest in product enhancements designed to help better manage their condition. This milestone in the ProAir brand shows our continued efforts to deliver the best treatment solutions that meet patients’ or their caregivers’ needs.”
Read the Teva press release.
